BioMaxima S.A. (WSE:BMX)

Market Cap	55.14M
Revenue (ttm)	56.60M
Net Income (ttm)	874.00K
Shares Out	4.19M
EPS (ttm)	0.21
PE Ratio	63.09
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,651
Average Volume	3,972
Open	13.15
Previous Close	13.15
Day's Range	13.05 - 13.30
52-Week Range	10.55 - 20.50
Beta	-0.16
RSI	45.06
Earnings Date	Aug 29, 2025

About Paramount Global

BioMaxima S.A. manufactures and distributes microbiological media, reagents, and equipment for in vitro diagnostics in Poland. Its primary products include analyzers and diagnostic reagents for testing the biochemical parameters of blood and other body fluids; systems for the determination of drug resistance of microorganisms; quick diagnostic tests for detecting infectious diseases, cancer markers, heart attack markers, and addictive substances and readers; urine analysis systems; hematology analyzers and reagents; ionselective analyzers and r...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1997
• Employees: 126
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: BMX

Financial Performance

In 2024, BioMaxima's revenue was 52.85 million, an increase of 12.96% compared to the previous year's 46.79 million. Earnings were 535,000, a decrease of -8.70%.